A Study of the Pharmacokinetics and Safety of BMS-663068 Administered in Subjects With Normal Renal Function and With Mild, Moderate, Severe and End Stage Renal Dysfunction (ESRD)
NCT02674581 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2018-05-15
Summary
An oral dose in healthy and renally impaired subjects to determine the drug effect for BMS-663068.
Conditions
- HIV Infections
Interventions
- DRUG
-
Oral BMS-663068 (pro-drug)
Oral BMS-663068 (pro-drug), metabolized to active BMS-626529
Sponsors & Collaborators
- collaborator INDUSTRY
-
ViiV Healthcare
lead INDUSTRY
Principal Investigators
-
GSK Clinical Trials · ViiV Healthcare
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2016-02-26
- Primary Completion
- 2016-05-24
- Completion
- 2016-05-24
Countries
- United States
Study Locations
More Related Trials
-
Study of Enfuvirtide in HIV-Positive Subjects
NCT00086710 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis
NCT02600819 ·Status: COMPLETED ·Phase: PHASE3
-
Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral-Naïve HIV-1 Infected Participants (MK-8558-002)
NCT03859739 ·Status: COMPLETED ·Phase: PHASE1
-
Impact of Drug Therapy and Co-Morbidities on the Development of Renal Impairment in HIV-Infected Patients
NCT00551655 ·Status: COMPLETED
-
Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance
NCT04150068 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral HRS5685 in Healthy Subjects
NCT05328583 ·Status: UNKNOWN ·Phase: PHASE1
-
Pharmacokinetics of Calcineurin & mTOR Inhibitors in HIV-1 Infected Kidney Transplant Recipients After Switch to BIC/FTC/TAF
NCT04993872 ·Status: UNKNOWN ·Phase: PHASE4
-
Measurement of Glomerular Filtration Rate (GFR) in HIV Patients: Single-center Study Comparing the Accuracy of Estimators of GFR Versus Iohexol Plasma Clearance
NCT02522338 ·Status: COMPLETED ·Phase: PHASE4
-
Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years
NCT02616783 ·Status: COMPLETED ·Phase: PHASE3
-
MARCH Renal Substudy
NCT01637259 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
NCT07053384 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Removal of Doravirine by Hemodialysis in HIV-Infected Patients With End-stage Renal Disease (ESRD)
NCT04689737 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
NCT01440569 ·Status: COMPLETED ·Phase: PHASE3
-
A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1
NCT01266902 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 Years
NCT03405935 ·Status: COMPLETED ·Phase: PHASE3
-
Oral Auranofin for Reduction of Latent Viral Reservoir in Patients With HIV Infection
NCT02176135 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
MK-8583 Single Dose Study in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8583-002)
NCT03552536 ·Status: COMPLETED ·Phase: PHASE1
-
Immunologic and Virologic Parameters During Analytical Treatment Interruption Following Combination bNAb Therapy During Suppressive ART
NCT06908083 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE1
-
Implementation of Onsite, Rapid ART Initiation Among People Who Inject Drugs Living With HIV at Syringe Services Program
NCT04650269 ·Status: COMPLETED ·Phase: PHASE4
-
D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults
NCT01565850 ·Status: COMPLETED ·Phase: PHASE2
-
Dynamics of Drug Resistance-associated Mutations in HIV-1 DNA Reverse Transcriptase Clearance During Effective Antiretroviral Therapy
NCT04448158 ·Status: COMPLETED
-
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
NCT02116660 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments
NCT06337032 ·Status: RECRUITING ·Phase: PHASE4
-
Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen
NCT02478632 ·Status: COMPLETED ·Phase: PHASE3
-
Open-Label Multi-Centre Randomised Switch Study to Evaluate Virological Efficacy Over 96Weeks Of 2-Drug Therapy With Dolutegravir(DTG)/Rilpivirine(RPV) Fixed Dose Combination(FDC) in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects Virologically Suppressed With NNRTI Mutation K103N
NCT05349838 ·Status: COMPLETED ·Phase: PHASE3